# Rizatriptan for Episodic Dizziness in Vestibular Migraine

> **NCT02447991** · PHASE2,PHASE3 · COMPLETED · sponsor: **Robert W. Baloh** · enrollment: 223 (actual)

## Conditions studied

- Vestibular Migraine
- Migrainous Vertigo

## Interventions

- **DRUG:** Rizatriptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02447991
- **Lead sponsor:** Robert W. Baloh
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2021-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02447991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02447991, "Rizatriptan for Episodic Dizziness in Vestibular Migraine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02447991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*